Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OYSTER POINT PHARMA, INC.

(OYST)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
14.06(c) 13.16(c) 13.29(c) 13.35(c) 13.1(c) Last
62 623 82 344 62 200 50 704 250 922 Volume
-2.50% -6.40% +0.99% +0.45% -1.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 6,75 M - -
Net income 2021 -106 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,34x
Yield 2021 -
Sales 2022 73,9 M - -
Net income 2022 -134 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,88x
Yield 2022 -
Capitalization 341 M 341 M -
Capi. / Sales 2021 50,5x
Capi. / Sales 2022 4,61x
Nbr of Employees 62
Free-Float 93,6%
More Financials
Company
Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The Company's lead product candidate is OC-01 (varenicline) nasal spray, a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms... 
More about the company
All news about OYSTER POINT PHARMA, INC.
09/01Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rul..
GL
08/05OYSTER POINT PHARMA : Management's Discussion and Analysis of Financial Conditio..
AQ
08/05OYSTER POINT PHARMA, INC. : Results of Operations and Financial Condition, Finan..
AQ
08/05OYSTER POINT PHARMA : Reports Second Quarter 2021 Financial Results and Recent B..
AQ
08/05OYSTER POINT PHARMA : Announces Exclusive License Agreement with Ji Xing Pharmac..
AQ
08/05Oyster Point Pharma, Inc. Reports Earnings Results for the Second Quarter End..
CI
08/05Oyster Point Pharma, Inc. Announces Exclusive License Agreement with Ji Xing ..
CI
08/04OYSTER POINT PHARMA : to Report Second Quarter 2021 Financial Results on August ..
AQ
08/03OYSTER POINT PHARMA : Announces New Chairperson Appointment to Board of Director..
PU
08/03OYSTER POINT PHARMA : Names Donald Santel as Non-Executive Chairman
MT
08/02Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rul..
GL
08/02OYSTER POINT PHARMA, INC. : Change in Directors or Principal Officers, Regulatio..
AQ
08/02OYSTER POINT PHARMA : Announces New Chairperson Appointment to Board of Director..
AQ
08/02Oyster Point Pharma Announces New Chairperson Appointment to Board of Directo..
CI
07/01OYSTER POINT PHARMA, INC. : Regulation FD Disclosure, Other Events, Financial St..
AQ
More news
News in other languages on OYSTER POINT PHARMA, INC.

- No features available -

More news
Chart OYSTER POINT PHARMA, INC.
Duration : Period :
Oyster Point Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OYSTER POINT PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 13,10 $
Average target price 55,50 $
Spread / Average Target 324%
EPS Revisions
Managers and Directors
Jeffrey A. Nau President, Chief Executive Officer & Director
Daniel Lochner Chief Financial Officer
Donald J. Santel Non-Executive Chairman
Marian Macsai Chief Medical Officer & Head-Medical Affairs
Eric Carlson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
OYSTER POINT PHARMA, INC.-30.39%341
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420